Home › Merkel Cell Carcinoma
Pag-aaral pangklinika para sa Merkel Cell Carcinoma na nagre-recruit sa U.S.
24 pag-aaral para sa Merkel Cell Carcinoma ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Houston, TX6 pag-aaral
- Boston, MA5 pag-aaral
- San Antonio, TX4 pag-aaral
- New York City, NY4 pag-aaral
- Tampa, FL4 pag-aaral
- Nashville, TN3 pag-aaral
- Washington, DC3 pag-aaral
- Los Angeles, CA3 pag-aaral
- St. Louis, MO3 pag-aaral
- Queens, NY3 pag-aaral
- Pittsburgh, PA3 pag-aaral
- Miami, FL3 pag-aaral
- Seattle, WA3 pag-aaral
- Jacksonville, FL3 pag-aaral
- Arlington, VA3 pag-aaral
Ayos sa estado
- California5 pag-aaral
- Florida11 pag-aaral
- Maryland3 pag-aaral
- Massachusetts5 pag-aaral
- Michigan5 pag-aaral
- Missouri3 pag-aaral
- New Jersey3 pag-aaral
- New York4 pag-aaral
- North Carolina3 pag-aaral
- Pennsylvania4 pag-aaral
- Tennessee3 pag-aaral
- Texas8 pag-aaral
- Virginia3 pag-aaral
- Washington4 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07285044Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05583708Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06047379Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Nagre-recruitPhase 1
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07006727Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Nagre-recruitPhase 1/2
Edad 18 hanggang 99 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06814496Studies of Dermatologic Diseases Biospecimen Acquisition Protocol
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
1 Day – 100 Years · Lahat ng kasarian · Na-update Set 22, 2026 · NCT02471352A Study of CRD3874-SI in People With Solid Tumors
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT06021626Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT05267626Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
Nagre-recruitPhase 2
Lahat ng edad · Lahat ng kasarian · Na-update Set 4, 2026 · NCT02479698Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 31, 2026 · NCT05896839Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Nagre-recruitPhase 1/2
Edad 16 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT05269381A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT07115043A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 12, 2026 · NCT05859074A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT05592626A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT07749586Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 16, 2026 · NCT05100095Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 25, 2026 · NCT04975152MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 11, 2026 · NCT05076760Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 17, 2026 · NCT06947928EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
Nagre-recruitPhase 2
Edad 18 hanggang 99 · Lahat ng kasarian · Na-update Mar 10, 2026 · NCT06223659Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 18, 2026 · NCT05496036TIL Therapy in cSCC and MCC
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 13, 2026 · NCT07288073IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 15, 2025 · NCT06940440A Beta-only IL-2 ImmunoTherapY Study
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 9, 2025 · NCT05086692Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.